

# **Real World Evidence / HEOR Publication List**

Publications as of June 2018

# HEOR publications

## Journal articles

1. Reynolds C, Masters ET, Black-Shinn J, Boyd M, Mardekian J, Espirito JL, Chioda M. Real-World Use and Outcomes of ALK-Positive Crizotinib-Treated Metastatic NSCLC in US Community Oncology Practices: A Retrospective Observational Study. *J Clin Med.* 2018;7(6).
2. Denduluri N, Lyman GH, Wang Y, Morrow PK, Barron R, Patt D, Bhowmik D, Li X, Bhor M, Fox P, Dhanda R, Saravanan S, Jiao X, Garcia J, Crawford J. Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer. *Clin Breast Cancer.* 2018.
3. Jiao X, Pulgar S, Boyd M, Braiteh F, Mirakhur B, Pitman Lowenthal S, Fox P, Frytak J, Cox D, Paulson AS. Treatment Patterns and Clinical Outcomes in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated in the Community Practice Setting in the United States. *Pancreas.* 2018;47(2):173-182.
4. Denduluri N, Morrow PK, Lyman GH. Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer. *Clinical Breast Cancer.* 2018.
5. Nadler E, Espirito J, Pavilack M, Boyd M, Vergara-Silva A, Ancilla F. Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small Cell Lung Cancer Patients Treated in the Community Practice Setting. *Clinical Lung Cancer.* 2018.
6. Paulson AS, Hess L, Liepa A, Cui Z, Aguilar K, Clark J, Schelman W. Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices. *Gastric Cancer.* 2018.
7. Robert NJ, Goertz HP, Chopra P, Jiao X, Yoo B, Patt D, Antao V. HER2-Positive Metastatic Breast Cancer Patients Receiving Pertuzumab in a Community Oncology Practice Setting: Treatment Patterns and Outcomes. *Drugs Real World Outcomes.* 2017.
8. Cowey CL, Liu FX, Black-Shinn J, Stevinson K, Boyd M, Frytak JR, Ebbinghaus SW. Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices. *J Immunother.* 2017.
9. Cowey CL, Mahnke L, Espirito J, Helwig C, Oksen D, Bharmal M. Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA. *Future Oncol.* 2017;13(19):1699-1710.
10. Bookman MA, Tyczynski JE, Espirito JL, Wilson TW, Fernandes AW. Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer. *Gynecol Oncol.* 2017.
11. Hoverman JR, Frytak J, Staggs S, Jackson G, Sarma A, Verrilli DK, Neubauer M. From angst to analytics: lessons learned from an oncology care model internal pilot. *JCSO.* 2017;16(e).
12. Di Bella NJ, Bhowmik D, Bhor M, Yap M, Middlebrook B, Rembert D, Cain Z, Okoro T, Bolinder B, Patt D, Jabbour EJ. The effectiveness of tyrosine kinase inhibitors and molecular monitoring patterns in newly diagnosed patients with chronic myeloid leukemia in the community setting. *Clin Lymphoma Myeloma Leuk.* 2015;15(10):599-605.
13. Denduluri N, Patt DA, Wang Y, Bhor M, Li X, Favret AM, Morrow PK, Barron RL, Asmar L, Saravanan S, Li Y, Garcia J, Lyman GH. Dose delays, dose reductions, and relative dose intensity in patients with cancer who received adjuvant or neoadjuvant chemotherapy in community oncology practices. *J Natl Compr Canc Netw.* 2015;13(11):1383-1393.
14. Chen C, Ravelo A, Yu E, Dhanda R, Schnadig I. Clinical outcomes with bevacizumab-containing and non-bevacizumab-containing regimens in patients with recurrent glioblastoma from US community practices. *J Neurooncol.* 2015;122(3):595-605.

15. Patt D, Rembert D, Corzo D. Treatment of metastatic breast cancer with -paclitaxel in the community practice setting: a US Oncology survey. *J Community Support Oncol.* 2015;13(5):173-180.
16. Vogelzang NJ, Hackshaw MD, Hutson TE, Bhowmik D, Yap M, Rembert D, Jonasch E. First-line and sequential use of pazopanib followed by mammalian target of rapamycin inhibitor therapy among patients with advanced renal cell carcinoma in a US community oncology setting. *Clin Genitourin Cancer.* 2015;13(3):210-217.
17. Sonpavde G, Bhor M, Hennessy D, Bhowmik D, Shen L, Nicacio L, Rembert D, Yap M, Schnadig I. Sequencing of cabazitaxel and abiraterone acetate after docetaxel in metastatic castration-resistant prostate cancer: treatment patterns and clinical outcomes in multicenter community-based us oncology practices. *Clin Genitourin Cancer.* 2015;13(4):309-318.
18. Yasenachak CA, Tseng WY, Yap M, Rembert D, Patt DA. Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma. *Leuk Lymphoma.* 2015;56(11):3143-3149.
19. Hoverman JR, Klein I, Harrison DW, Hayes JE, Garey JS, Harrell R, Sipala M, Houldin S, Jameson MD, Abdullahpour M, McQueen J, Nelson G, Verrilli DK, Neubauer M. Opening the black box: the impact of an oncology management program consisting of level I pathways and an outbound nurse call system. *J Oncol Pract.* 2014;10(1):63-67.
20. Schnadig ID, Hutson TE, Chung H, Dhanda R, Halm M, Forsyth M, Vogelzang NJ. Dosing patterns, toxicity, and outcomes in patients treated with first-line sunitinib for advanced renal cell carcinoma in community-based practices. *Clin Genitourin Cancer.* 2014;12(6):413-421.
21. Chen C, Borker R, Ewing J, Tseng WY, Hackshaw MD, Saravanan S, Dhanda R, Nadler E. Epidemiology, treatment patterns, and outcomes of metastatic soft tissue sarcoma in a community-based oncology network. *Sarcoma.* 2014;2014:145764.
22. Patt D, Rembert D, Bhor M, Bhowmik D, Rao SA. A real-world observational study of patients with advanced melanoma receiving first-line ipilimumab in a community practice setting. *J Cancer Ther.* 2014;5(12):1049-1058.
23. Kolibaba KS, Sterchele JA, Joshi AD, Forsyth M, Alwon E, Beygi H, Kennealey GT. Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study. *Ther Adv Hematol.* 2013;4(3):157-171.
24. Vogelzang NJ, Bhor M, Liu Z, Dhanda R, Hutson TE. Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network. *Clin Genitourin Cancer.* 2013;11(2):115-120.
25. Chen C, Dhanda R, Tseng WY, Forsyth M, Patt DA. Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer. *J Oncol Pract.* 2013;9(4):182-187.
26. Pan IW, Mallick R, Dhanda R, Nadler E. Treatment patterns and outcomes in patients with non-squamous advanced non-small cell lung cancer receiving second-line treatment in a community-based oncology network. *Lung Cancer.* 2013;82(3):469-476.
27. Landis SH, Chen C, Byrne JA, Jones SE, Dhanda R, Nelson JJ. Assessment of physician compliance to liver function test monitoring guidance for patients treated with lapatinib. *Community Oncology.* 2013;10(9):258-265.
28. Sharma PP, Sail K, Delea TE, Patt D. Treatment patterns in HER2+/HR+ postmenopausal women with metastatic breast cancer initiating first-line treatment in a community oncology setting in the US. *Community Oncology.* 2013;10(3):74-81.
29. Wang Z, Askamit I, Tuscher L, Bergstrom K. Rates of guideline adherence among US community oncologists treating NSCLC. *Am J Manag Care.* 2013;19(3):185-192.
30. Cartwright TH, Yim YM, Yu E, Chung H, Halm M, Forsyth M. Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology. *Clin Colorectal Cancer.* 2012;11(4):238-246.

31. Beveridge R, Satram-Hoang S, Sail K, Darragh J, Chen C, Forsyth M, Reyes C. Economic impact of disease progression in follicular non-Hodgkin lymphoma. *Leuk Lymphoma*. 2011;52(11):2117-2123.
32. Hoverman JR, Cartwright TH, Patt DA, Espirito JL, Clayton MP, Garey JS, Kopp TJ, Kolodziej M, Neubauer MA, Fitch K, Pyenson B, Beveridge RA. Pathways, outcomes, and costs in colon cancer: retrospective evaluations in two distinct databases. *J Oncol Pract*. 2011;7(3 Suppl):52s-59s.
33. Muehlenbein CE, Hoverman JR, Gruschkus SK, Forsyth M, Chen C, Lopez W, Lawson A, Hartnett HJ, Pohl G. Evaluation of the reliability of electronic medical record data in identifying comorbid conditions among patients with advanced non-small cell lung cancer. *J Cancer Epidemiol*. 2011;2011:983271.
34. Nadler E, Yu E, Ravelo A, Sing A, Forsyth M, Gruschkus S. Bevacizumab treatment to progression after chemotherapy: outcomes from a U.S. community practice network. *Oncologist*. 2011;16(4):486-496.
35. Neubauer MA, Hoverman JR, Kolodziej M, Reisman L, Gruschkus SK, Hoang S, Alva AA, McArthur M, Forsyth M, Rothermel T, Beveridge RA. Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting. *J Oncol Pract*. 2010;6(1):12-18.
36. Conner TM, Doan QD, Walters IB, LeBlanc AL, Beveridge RA. An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma. *Clin Lymphoma Myeloma*. 2008;8(3):140-145.

## Conference abstracts

37. Doshi G, Bhanegaonkar A, Bharmal M, Phatak H, Boyd M, Aguilar K, Kim R, Cislo P, Kearney M. Patient characteristics and treatment patterns from SPEAR-BLADDER: Study informing treatment Pathway decision in bladder cancer. ISPOR; May 19-21, 2018; Baltimore, MD.
38. Cowey CL, Ghate S, Rhodes WC, Wilson T, Ndife B, Espirito J, Borker R, Frytak J, Nakasata AR, Robert N. Adjuvant therapy utilization among stage III melanoma patients. ASCO; June 1-5, 2018; Chicago, IL.
39. Doshi G, Bhanegaonkar A, Bharmal M, Phatak H, Aguilar K, Kearney M. SPEAR-Bladder (Study informing treatment Pathway dECision in bladder cAnceR): first- through third-line time to treatment failure in the US. ASCO; June 1-5, 2018; Chicago, IL.
40. Cowey CL, Liu FX, Black-Shinn J, Stevinson K, Boyd M, Frytak J, Ebbinghaus S. Real world utilization and outcomes of pembrolizumab for the treatment of patients with advanced melanoma in US community oncology practice. International Congress of the Society for Melanoma Research; October 18–21, 2017; Brisbane, Australia.
41. Cartwright T, Parisi M, Espirito JL, Wilson T, Pelletier C, Patel M, Babiker HM. Large retrospective study of outcomes and supportive care use in metastatic pancreatic adenocarcinoma patients treated with first-line nab-paclitaxel + gemcitabine and FOLFIRINOX. AMCP Nexus; Oct 16-19, 2017.
42. Bookman MA, Espirito JL, Wilson T, Fernandes A. Chemotherapy costs, but not resource utilization, are inversely correlated with the primary platinum-free interval among outpatients with recurrent ovarian cancer. Society of Gynecologic Oncology Annual Meeting; March 15-17, 2017.
43. Cartwright T, Parisi M, Espirito JL, Wilson T, Pelletier C, Patel M, Babiker HM. Treatment outcomes with first-line (1L) nab-Paclitaxel + gemcitabine (AG) and FOLFIRINOX (FFX) in metastatic pancreatic adenocarcinoma ASCO; June 2-6, 2017; Chicago, IL.
44. Cowey CL, Liu FX, Black-Shinn J, Stevinson K, Boyd M, Patt D, Ebbinghaus S. An Observational Study of Patients with Advanced Melanoma Receiving Pembrolizumab in Real World US Community Oncology Practice ASCO; June 2-6, 2017; Chicago, IL.
45. Nadler E, Espirito JL, Pavilack M, Boyd M, Vergara-Silva A, Fernandes A. Understanding treatment patterns and outcomes in patients with metastatic NSCLC treated in a US Community oncology network. ASCO; June 2-6, 2017; Chicago, IL.
46. Nadler E, Joo S, Black-Shinn J, Boyd M, Zhuo J, Chirovsky D. Treatment patterns in recurrent/metastatic head and neck squamous cell carcinoma in the US. ASCO; June 2-6, 2017; Chicago, IL.
47. Panjabi S, Medhekar R, Aguilar K, Wilson T, Amirian ES, Mezzi K, Rifkin RM. Real-world treatment patterns of adult multiple myeloma patients treated with carfilzomib in the US community oncology setting. ASCO; June 2-6, 2017; Chicago, IL.
48. Rifkin RM, Medhekar R, Mezzi K, Aguilar K, Wilfong LS, Amirian ES, Panjabi S. Characteristics of adult multiple myeloma patients receiving carfilzomib in a US community oncology setting. ASCO; June 2-6, 2017; Chicago, IL.
49. Flannery K, Black-Shinn J, Boyd M, Kamat A. Real world treatment utilization and outcomes of patients with metastatic bladder cancer by cisplatin eligibility in US community oncology practice. ASCO; June 2-6, 2017; Chicago, IL.
50. Rifkin RM, Amirian ES, Medhekar R, Wilson T, Boyd M, Mezzi K, Panjabi S. Carfilzomib Dosing Patterns and Time to Next Treatment Among Adult Patients with Multiple Myeloma Treated in the US Community Oncology Setting. ASH Annual Meeting; Dec 9-12, 2017; Atlanta, CA.

51. Rifkin RM, Medhekar R, Amirian ES, Wilson T, Boyd M, Mezzi K, Panjabi S. A Real-World Comparative Analysis of Carfilzomib and Other Systemic Multiple Myeloma Chemotherapies in the US Community Oncology Setting. ASH Annual Meeting; Dec 9-12, 2017; Atlanta, CA.
52. Sharman J, Black-Shinn J, Clark J, Bitman B. Understanding Ibrutinib Treatment Discontinuation Patterns for Chronic Lymphocytic Leukemia. ASH Annual Meeting; Dec 9-12, 2017; Atlanta, CA.
53. Sharman J, Black-Shinn J, Clark J, Karve S. MCL Treatment Patterns and Outcomes: A Community Oncology Practice Experience. ASH Annual Meeting; Dec 9-12, 2017; Atlanta, CA.
54. Yassenchak CA, Feliciano J, Aguilar K, Clark J, Amirian ES, Richhariya A. Clinical Profiles, Treatment Characteristics and Outcomes among Newly Diagnosed Hodgkin lymphoma Patients Presenting with Unfavorable and Advanced Disease within a US Community Oncology Setting. ASH Annual Meeting; Dec 9-12, 2017; Atlanta, CA.
55. Flannery K, Black-Shinn J, Boyd M, Robert L, Kamat A. Second-line treatment patterns and outcomes of metastatic bladder cancer patients in clinical practice. ESMO; 2017.
56. Schelman W, Paulson AS, Aguilar K, Clark J, Cui Z, Liepa A, Hess L. Predictive factors associated with ramucirumab monotherapy or combination therapy among patients with gastric/gastroesophageal junction cancer in the community oncology setting ESMO World Congress on Gastrointestinal Cancer; 2017; Barcelona, Spain.
57. Pulger SJ, Jiao X, Mirakhur B, Lowenthal SP, Braiteh FS, Boyd M, Fox P, Frytak J, Cox D, Paulson AS. Treatment patterns, clinical outcomes, and health care resource utilization in patients with metastatic gastroenteropancreatic neuroendocrine tumors (mGEP-NETs). NANETS; Sept 30 - Oct 1, 2016; Jackson, WY.
58. Cowey CL. Real-world outcomes of patients with metastatic merkel cell carcinoma treated with second-line or later chemotherapy in a community oncology setting in the United States. ISPOR Annual European Congress Oct. 29 - Nov. 2, 2016; Vienna, Austria.
59. Hirsch BR, Jiao X, Williams S, Hackshaw MD, Jonasch E, Ghate S, Ricardo Perez J, Vogelzang NJ. Treatment patterns and clinical outcomes in pazopanib compared to sunitinib as first line therapy for patients with advanced/metastatic renal cell carcinoma (aRCC) in a US community oncology setting ISPOR; May 21-25, 2016; Washington, DC.
60. Bookman MA, Tyczynski JE, Espirito JL, Wilson T, Fernandes A. Sustained impact of primary platinum-free interval and BRCA1/2 mutation status on survival in patients with ovarian cancer after multiple lines of therapy. ASCO; Jun 3-7, 2016; Chicago, IL.
61. Patt D, Jiao X, Fonseca E, Clark J, Fox P, Horblyuk R, McRoy L, Mardekian J, Arondekar B. Real-world use of first-line chemotherapy in post-menopausal patients with HR-positive HER2-negative metastatic breast cancer (mBC) in a US community oncology network ASCO Annual Meeting; Jun 3-7, 2016; Chicago, IL.
62. Patt D, Mitra D, Harrell R, Espirito JL, Perkins JJ, McRoy L, Arondekar B. Early treatment utilization of palbociclib for metastatic breast cancer (MBC) in a U.S. community oncology network. ASCO; Jun 3-7, 2016; Chicago, IL.
63. Jiao X, Pulger SJ, Boyd M, Braiteh FS, Pitman Lowenthal S, Cox D, Fox P, Paulson AS. Treatment patterns and clinical outcomes of patients with metastatic gastroenteropancreatic neuroendocrine tumors (mGEP-NETs). Gastrointestinal Cancers Symposium; Jan 21-23, 2016; San Francisco, CA.
64. Hirsch BR, Jiao X, Wilson T, Hackshaw MD, Jonasch E, Ghate S, Ricardo Perez J, Vogelzang NJ. Comparative effectiveness of pazopanib and sunitinib as first line therapy for patients with advanced/metastatic renal cell carcinoma in a US community oncology setting Genitourinary Cancers Symposium; Jan 7-9, 2016.
65. Hustson T, Jiao X, Wilson T, Cisar LA, MacLean EA. Axitinib treatment among patients with mRCC in a U.S. community oncology setting: A retrospective study of 135 patients. Genitourinary Cancers Symposium; Jan 7-9, 2016; San Francisco, CA.

66. Patt D, Fonseca E, Yoo B, Wilson T, Goertz HP, Lai C. Real world treatment patterns and outcomes in HER2 positive MBC patients with brain metastasis in the US community oncology setting. ASCO Quality Care Symposium; Feb 26-27, 2016; Phoenix, AZ.
67. Burke JM, Black-Shinn J, Clark J, Frytak J, Espirito JL, Sharman J. Management of elderly patients with diffuse large B-cell lymphoma in a network of community oncology practices in the United States. ASH; December 3-6, 2016; San Diego, CA.
68. Robert N, Goertz HP, Chopra P, Jiao X, Yoo B, Patt D, Antao V. Clinical characteristics, treatment patterns, and outcomes for patients with HER2-positive metastatic breast cancer treated with pertuzumab in the first-line in a real-world setting. European Cancer Congress; Sept 25-29, 2015; Vienna, Austria.
69. Rifkin RM, Fonseca E, Chen YJ, Fox PS, Browning JE, Cong Z. Carfilzomib dosing patterns and survival in patients with relapsed and refractory multiple myeloma: an analysis from US community oncology practices. Annual Meeting of the American Society of Hematology; Dec. 5-8, 2015; Orlando, FL.
70. Robert N, Goertz HP, Jiao X, Yoo B, Patt D, Antao V. Pertuzumab (P) use in first-line HER2-positive metastatic breast cancer (mBC) in US community oncology practices: Treatment patterns and outcomes. San Antonio Breast Cancer Symposium; Dec 8-12, 2015; San Antonio, TX.
71. Hutson TE, Hackshaw MD, Vogelzang NJ, Bhowmik D, Yap M, Rembert D, Jonasch E. Outcomes of advanced renal cell carcinoma patients (aRCC) treated with mammalian target of rapamycin inhibitor (mTORi) therapy following first-line pazopanib (PAZ) in a US Community Oncology Setting. ESMO; Sept 26-30, 2014; Madrid, Spain.
72. Vogelzang NJ, Hackshaw MD, Hutson TE, Bhowmik D, Yap M, Rembert D, Jonasch E. Outcomes of advanced renal cell carcinoma patients (aRCC) treated with first-line pazopanib (PAZ) in a US community oncology setting. ESMO; Sept 26-30, 2014; Madrid, Spain.
73. Cartwright T, Pan I, Wen L, Wadlow RC, Rembert D, Seal B. Treatment patterns and outcomes in metastatic colorectal cancer (mCRC) patients treated in a community oncology setting. ISPOR Annual International Meeting; May 31-Jun4, 2014; Montreal, QC, Canada.
74. Espirito JL, Turnwald B, Harrell RK, Bhowmik D, Denduluri N, Brooks BD, Hoverman JR, Beveridge RA, Patt D. Bridging to survivorship in breast cancer: How BMI weighs in. ASCO Annual Meeting; May 31- Jun 4, 2014; Chicago, IL.
75. Patt D, Liang C, Li L, Ko A, Duval Fraser C, Corzo D, Enger C. Real-world safety and efficacy of nab-paclitaxel in patients with metastatic breast cancer (mBC) treated in the united states: results from a health insurance database. ISPOR Annual International Meeting; May 31 - Jun 4, 2014; Montreal, QC, Canada.
76. Patt D, Richardson P, Rembert D, Corzo D, Chen C. Treatment of patients (pts) with HER2- metastatic breast cancer (MBC) with nab-paclitaxel (nab-P) in the clinical practice setting—Results of a US Oncology survey. ASCO Annual Meeting; May 30 - June 3, 2014; Chicago, IL.
77. Kumar SK, Engebretson AE, Baudi FK, Lacy MQ, Dispenzieri A, Duh MS, Lafeuille M, Lefebvre P, Cheng W, Dea K, Yap M, Saravanan S, Pan I, Rembert D, Patt D, Niculescu L, Ma E, Quick M, Rajkumar SV. Comparable outcomes and lower total healthcare cost with bortezomib-cyclophosphamide-dexamethasone (VCD) compared to bortezomib-lenalidomide-dexamethasone (VRD) for initial treatment of newly diagnosed multiple myeloma (MM). Association for Value-Based Cancer Care May 6-9, 2014; Los Angeles, CA.
78. Kolibaba KS. Treatment response monitoring in chronic phase CML (CP-CML) patients receiving tyrosine kinase inhibitor (TKI) therapy in US Oncology network. ASCO Annual Meeting; May 31-Jun 4, 2013; Chicago, IL.
79. Neubauer M, Garey JS, Turnwald B, Harrell RK, Howell J, Hayes J, Bhowmik D, Hoverman JR, Brooks BD, Beveridge RA. Impact of pathways on chemotherapy administration before death. ASCO Annual Meeting; May 31-Jun 4, 2013; Chicago, IL.

80. Patt D, Espirito JL, Turnwald B, Harrell RK, Bhowmilk D, Hoverman JR, Brooks BD, Denduluri N, Beveridge RA. Bridging to survivorship in breast cancer: Learning how treatment impacts mental health among early-stage breast cancer survivors. ASCO Annual Meeting; May 31-Jun 4, 2013; Chicago, IL.
81. Cartwright T, Ginsburg AL, Wilfong LS, Harrell RK, Hoverman JR, Beveridge RA. Use of an electronic health record (iKnowMed), in conjunction with evidence-based pathways, for data capture and outcome measurement in colorectal cancer patients treated with first-line therapy in the US Oncology Network. ASCO Annual Meeting; May 31-Jun 4, 2013; Chicago, IL.
82. Chen C, Chen L, Dhanda R, Chung H, Bhowmilk D, Ericson S, DiBella N. Types, frequency, and adherence of molecular tests in chronic myelogenous leukemia at chronic phase (CML-CP) in the U.S. community setting. ASCO Annual Meeting; May 31- Jun 4, 2013; Chicago, IL.
83. Pan I, Mallick R, Dhanda R, Nadler E. Treatment patterns, biomarker testing, and outcomes in patients with nonsquamous non-small cell lung cancer (NSCLC) receiving second-line treatment in the US Oncology network. ASCO Annual Meeting; May 31 - Jun 4, 2013; Chicago, IL.
84. Bhor M, Winfree KB, Sail K, Zagar A, Pohl G, Dhanda R. Evaluation of survival outcomes in select first-line treatment regimens for advanced nonsquamous non-small cell lung cancer patients. ISPOR Annual International Meeting; May 18-22, 2013; New Orleans, LA.
85. Schanadig ID, Bhor M, Vogelzang NJ, Hennessy BT, Nicacio LV, Berry WR, Hutson TE, Fleming MT, Cowey CL, Saravanan S, Dhanda R, Sonpavde G. Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC). Genitourinary Cancers Symposium; Feb 14-16, 2013; Orlando, FL.
86. Denduluri N, Bhor M, Bhowmik D, Morrow PK, Watson D, Dhanda R, Li X, Chung H, Saravanan S, Barron RL, Crawford J. Relative dose intensity of taxane-based chemotherapy in patients with stage IV breast cancer. San Antonio Breast Cancer Symposium; Dec 10-14, 2013; San Antonio, TX.
87. Jones SE, Tseng WY, Saravanan S, Santos E, Dhanda R, Rembert D, Yap M, Lalla D, Brammer M. Retrospective analysis of long-term survivors with HER2+ metastatic breast cancer (MBC) treated with trastuzumab in a community setting. San Antonio Breast Cancer Symposium; Dec 10-14, 2013; San Antonio, TX.
88. Li S, Favret AM, Bhor M, Barron RL, Denduluri N, Dhanda R, Saravanan S, Morrow PK, Langeberg W, Giradi V, Lyman GH. Dose delays, dose reductions, and relative dose intensity in early stage breast cancer patients receiving (neo)adjuvant chemotherapy in community oncology practices. San Antonio Breast Cancer Symposium; Dec 10-14, 2013; San Antonio, TX.
89. Di Bella NJ, Bhowmik D, Bhor M, Yap M, Middlebrook B, Rembert D, Dhanda R, Cain Z, Okoro T, Bolinder B, Jabbour EJ. Association between treatment adherence and response among patients with chronic myeloid leukemia (CML) receiving first-line TKIs in the community setting. Annual Meeting of the American Society of Hematology; Dec 7-10, 2013; New Orleans, LA.
90. Kumar SK, Engebretson AE, Buadi FK, Lacy MQ, Dispenzieri A, Sheng Duh M, Lafeuille M, Lefebvre P, Cheng W, Dea K, Yap M, Saravanan S, Rembert D, Patt D, Niculescu L, Ba-Mancini A, Ma E, Rajkumar SV. Comparable outcomes and lower total healthcare cost with bortezomib-cyclophosphamide-dexamethasone (VCD) compared to bortezomib-lenalidomide-dexamethasone (VRD) for initial treatment of newly diagnosed multiple myeloma (MM). Annual Meeting of the American Society of Hematology; Dec 7-10, 2013; New Orleans, LA.
91. Rifkin RM, Chen C, Dhanda R, Rembert D, Ba-Mancini A, Ma E, Zhu Y, Dow E, Niculescu L. Impact of route of bortezomib (B) administration on dose intensity and time to dose reduction in previously untreated patients (pts) With multiple myeloma (MM). Annual Meeting of the American Society of Hematology; Dec 7-10, 2013; New Orleans, LA.
92. Chen C, Ravelo A, Yu E, Dhanda R, Schanadig ID. Overall survival and progression-free survival with bevacizumab and non-bevacizumab-containing regimens in patients With recurrent glioblastoma from US community practices. SNO Annual Meeting; Nov 15-18, 2012; Washington, DC.



93. Bhor M, Hutson TE, Dhanda R, Liu Z, Vogelzang NJ. Retrospective data study evaluating resource utilization among metastatic renal cell carcinoma patients receiving oral versus intravenous mTOR inhibitors. ASCO Annual Meeting; Jun 1-5, 2012; Chicago, IL.
94. Chen C, Borker R, Dhanda R, Nadler E. Treatment practice patterns and survival among patients with metastatic soft tissue sarcoma (mSTS) in a community setting in the United States. ASCO Annual Meeting; Jun 1-5, 2012; Chicago, IL.
95. Schanadig ID, Hutson TE, Chung H, Dhanda R, Halm M, Forsyth M, Vogelzang NJ. Sunitinib dosing, toxicity, and outcomes in first-line advanced renal cell carcinoma (aRCC): A U.S. Oncology Network (USON) retrospective study. ASCO Annual Meeting; Jun 1-5, 2012; Chicago, IL.
96. Nadler E, Sail K, Chen C, Thompson JA, Kolodziej M. Retrospective observational study: Bevacizumab (B) use and outcomes among metastatic colorectal cancer (mCRC) patients (pts) receiving care in the outpatient community in the United States. Gastrointestinal Cancers Symposium; Jan 19-21, 2012; San Francisco, CA.
97. Landis SH, Chen C, Dhanda R, Nelson JJ. Assessment of physician compliance to recommended liver function test monitoring. International Conference for Pharmacoepidemiology; Aug 23-26, 2012; Barcelona, Spain.
98. Cartwright T. Survival outcomes with the use of bevacizumab beyond progression in metastatic colorectal cancer patients. European Multidisciplinary Cancer Congress Sept 28, 2011; Stockholm, Sweden.
99. Patt D, Espirito JL, Turnwald B, Hoverman JR, Neubauer M, Busby LT, Brookes M, Kolodziej R, Anderson W, Beveridge RA. Utilization of pegfilgrastim in adjuvant chemotherapy regimens for breast cancer in the community. Breast Cancer Symposium; Sept 8-10, 2011; San Francisco, CA.
100. Chen C, Patt D, Kazzaz DR, Shankleton JA, Forsyth M, Ganesh R. Evaluating utilization characteristics for the Oncotype DX recurrence score in early-stage breast cancer. ASCO Annual Meeting; Jun 3-7, 2011; Chicago, IL.
101. Ginsburg AL, Patt D, Flinn J, Espirito JL, Neubauer M, Cartwright T, Hoverman JR, Busby LT, Brooks BD, Kolodziej M, Sitarik R, Anderson W, Beveridge RA. Understanding male breast cancer in the community setting. ASCO Annual Meeting; Jun 3-7, 2011; Chicago, IL.
102. Joshi AD, Forsyth M, Fryefield DC, Lopez W, Chen DM, Ramanan DD. Demographic and treatment characteristics for advanced basal cell carcinoma (aBCC) in an oncology outpatient setting. ASCO Annual Meeting; Jun 3-7, 2011; Chicago, IL.
103. Kazzaz DR, Chang SM, Shankleton JA, Forsyth M, Ganesh R, Sims M, Patt D. Evaluation of relation between Oncotype DX recurrence score and adjuvant chemotherapy administration. ASCO Annual Meeting; Jun 3-7, 2011; Chicago, IL.
104. Neubauer M, Garey JS, Nelson GC, Patt D, Cartwright T, Hoverman JR, Busby LT, Brookes M, Sitarik R, Kolodziej R, Anderson W, Beveridge RA. Bevacizumab therapy in advanced non-small cell lung cancer (NSCLC): Outcomes from a community oncology network. ASCO Annual Meeting; Jun 3-7, 2011; Chicago, IL.
105. Patt D, Espirito JL, Turnwald B, Hoverman JR, Neubauer M, Cartwright T, Brooks BD, Busby LT, Sitarik MA, Kolodziej M, Ginsburg AL, Sheth S, Garey JS, Clayton GCN, R.W., Anderson W, Beveridge RA. Utilization and relative value of breast cancer adjuvant chemotherapy regimens in the community. ASCO Annual Meeting; Jun 3-7, 2011; Chicago, IL.
106. Sail K, Lalla D, Brammer M, Halm M, Patt D. Treatment patterns in patients with HER2-positive early-stage breast cancer (ESBC) receiving adjuvant treatment with a trastuzumab-containing regimen. ASCO Annual Meeting; Jun 3-7, 2011; Chicago, IL.
107. Sharma PP, Sail K, Delea TE, Forsyth M, Halm M, Nagarwala M, Lopez W, Patt D. Patterns of care and patient characteristics in postmenopausal women with HER2+ and hormone receptor-positive (HR+) metastatic breast cancer (MBC). ASCO Annual Meeting; Jun 3-7, 2011; Chicago, IL.

108. Kolibaba KS, Joshi AD, Sterchele JA, Forsyth M, Alwon E, Beygi H, Kennealey GT. Demographics, treatment patterns, safety, and real-world effectiveness in patients  $\geq 70$  years of age with chronic lymphocytic leukemia receiving bendamustine with or without rituximab. American Society of Hematology Annual Meeting; Dec 10-13, 2011; San Diego, CA.
109. Patt D, Espirito JL, Turnwald B, Hoang SNH, J.R. Ixabepilone alone and in combination with chemotherapy in the community setting. Breast Cancer Symposium; Oct 18-20, 2010; Suburban Washington, D.C.
110. Brammer M, Gruschkus S, Lalla D, Doan JF, Forsyth M. HER2 status and trastuzumab use among patients with early breast cancer receiving care within the US Oncology network. ESMO; Oct 8-12, 2010; Milan, Italy.
111. Ravelo A, Nadler E, Yu E, Sing A, Forsyth M, Gruschkus S. Bevacizumab (BV) treatment (Tx) to progression (BTP): outcomes from a US community practice network. ESMO; Oct 8-12, 2010; Milan, Italy.
112. Gruschkus S, Reyes C, Forsyth M, Nadler E, Ravelo A. Economic outcomes among 2nd line non-small cell lung cancer patients in the outpatient community setting. ISPOR Annual European Congress; Nov 6-9, 2010; Prague, Czech Republic.
113. Hoverman JR, Pohl G, Gruschkus S, Marciniak M, Forsyth M, Peltz G. Cost-effectiveness of 1st line chemotherapy regimens in the treatment of NSCLC among patients receiving care in the outpatient community setting. ISPOR; May 15-19, 2010; Atlanta, GA.
114. Muehlenbein CE, Hoverman JR, Gruschkus S, Forsyth M, Chen C, Lopez W, Lawson A, Hartnett HJ, Phol G. Evaluation of the reliability of electronic medical record data in identifying co-morbid conditions among patients with advanced NSCLC. ISPOR; May 15-19, 2010; Atlanta, GA.
115. Hoverman JR, Gruschkus SK, Muehlenbein CE, Forsyth M, Chen C, Lawson AH, Pohl G. Impact of comorbidities on clinical and economic outcomes among patients with advanced non-small cell lung cancer (NSCLC) receiving care in the community-based outpatient setting. ASCO Annual Meeting; June 4-10, 2010; Chicago, IL.
116. Chen C, Gruschkus S, Liu Z, Vogelzang NJ, Forsyth M, Lopez W, Hutson TE. Observational study evaluating resource utilization among metastatic renal cell carcinoma patients treated with mTOR inhibitors in the outpatient community-based setting. ASCO Annual Meeting; Jun 4-8, 2010; Chicago, IL.
117. Gruschkus SK, Doan JF, Chen C, Forsyth M, Lalla D, Shing M. First-line patterns of care and outcomes of HER2-positive breast cancer patients who progressed after receiving adjuvant trastuzumab in the outpatient community setting. ASCO Annual Meeting; Jun 4-8, 2010; Chicago, IL.
118. Neubauer M, Espirito JL, Clayton GC, Patt D. Combination versus sequential chemotherapy for metastatic breast cancer: An evaluation of outcomes from a community oncology network. ASCO Annual Meeting; Jun 4-8, 2010; Chicago, IL.
119. Beveridge R, Satram-Hoang S, Sail K, Darragh J, Chen C, Forsyth M, Reyes C. Economic impact of disease progression in follicular non-Hodgkin lymphoma. ASH Meeting and Exposition; Dec 10-13, 2010; Orlando, FL.
120. Gruschkus S, Darragh J, Forsyth M, Beveridge R, Reyes C. Economic impact of disease progression in follicular non-hodgkin's lymphoma. American Society of Hematology Annual Meeting; Dec 4-7, 2010; Orlando, FL.
121. Hoverman JR, Phol G, Gruschkus S, Marciniak M, Forsyth M, Peltz G. Clinical outcomes of 2nd line advanced NSCLC patients receiving monotherapy in the outpatient community setting. IASCL/ESMO Lung Cancer Conference; Apr 28, 2010; Geneva, Switzerland.
122. Forsyth M, Shankleton JA, Cardona-Pelaez JN, Khursigara G. Variability of flow cytometry screening for paroxysmal nocturnal hemoglobinuria in five community based oncology practices. Annual Meeting of the Clinical Cytometry Society Oct 16-18, 2009; Jacksonville, FL.

123. Gruschkus SK, Shankleton JA, Brammer M, Forsyth M, Lalla D. Patterns of care and outcomes among HER2-positive metastatic breast cancer patients receiving trastuzumab in the community setting. Breast Cancer Symposium; Oct 8-10, 2009; San Francisco, CA.
124. Gruschkus SK, Shankleton JA, Brammer M, Forsyth M, Lalla D. First-line trastuzumab utilization: Patterns of care and progression in the community setting. ASCO Annual Meeting; May 29-Jun 2, 2009; Orlando, FL.
125. Gruschkus S, Shankleton JA, Brammer M, Forsyth M, Lalla D. Trastuzumab use and community-based outpatient healthcare utilization among metastatic breast cancer patients. Miami Breast Cancer Conference; Jun 17-19, 2009; Miami, FL.
126. Conner TM, Hoverman JR, Forsyth M, Rascati K. Cost analysis of immunoglobulin prophylaxis in lymphocytic leukemia. ISPOR Annual International Conference; May 3-7, 2008; Toronto, Canada.